Mifegyne (Mifepristone)

Mifepristone blocks progesterone receptors, leading to breakdown of the uterine lining and detachment of the gestational sac. It also antagonises glucocorticoid receptors, which can lower cortisol activity, explaining its off‑label use in Cushing's syndrome.

The dosage of Mifegyne is determined by the prescribing clinician based on the indication, gestational age, and local guidelines. Typically a single 200 mg oral tablet is used for early pregnancy termination, but exact regimens must be confirmed by a qualified health professional.

Mifegyne is classified as Pregnancy Category X, meaning it is contraindicated in ongoing pregnancies except when used for intentional termination. It is not recommended for breastfeeding mothers because it may pass into breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mifegyne (mifepristone) is the most widely used oral abortifacient and is typically combined with misoprostol for higher efficacy. Compared with methotrexate‑based regimens, mifepristone offers a shorter treatment course and higher success rates for early pregnancy termination.

Mifegyne tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. This helps maintain potency and prevents degradation of the active ingredient.

Mifegyne is taken orally as a single 200 mg tablet. For medical abortion, it is usually followed 24–48 hours later by a dose of misoprostol taken buccally, sublingually, vaginally, or orally, according to the prescribing protocol.

Serious risks include heavy or prolonged uterine bleeding, severe infection (sepsis), allergic reactions such as anaphylaxis, liver injury, and, rarely, uterine rupture. Patients should be monitored closely for these events and seek immediate medical attention if they occur.

Mifegyne should not be used by individuals with confirmed or suspected ectopic pregnancy, chronic adrenal insufficiency, severe anemia, anticoagulant therapy, or known hypersensitivity to mifepristone. It is also contraindicated in patients who are not candidates for medical abortion based on gestational age or health status.